Experience of prophylaxis treatment in children with severe haemophilia

被引:65
|
作者
Yee, TT
Beeton, K
Griffioen, A
Harrington, C
Miners, A
Lee, CA
Brown, SA
机构
[1] UCL Royal Free & Univ Coll Med Sch, Haemophilia Ctr, Dept Primary Care & Populat Sci, London NW3 2QG, England
[2] UCL Royal Free NHS Trust, Haemophilia Ctr, London, England
[3] UCL Royal Free NHS Trust, Haemostasis Unit, London, England
[4] Univ Hertfordshire, Hatfield AL10 9AB, Herts, England
关键词
haemophilia; prophylaxis; joint scores; Port-a-Cath; inhibitor;
D O I
10.1046/j.1365-2516.2002.00630.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The practice of prophylactic treatment of boys with severe haemophilia has been evaluated in our centre. Prophylaxis was started at the median age of 3.7 years (range 0.4-12.7 years) in 38/41 children (93%) under 17 years of age. Median follow-up was 4.1 years (range 0.4-12.7 years). The criteria of primary prophylaxis according to the definition by the European Paediatric Network of Haemophilia Management was fulfilled by 9/38 (24%). Although a majority [76%, 29/38] of the children started prophylaxis after a median number of joint bleeds of 3.5, 70% of the children in this group had clinical joint scores of 0. Intravenous catheter insertion was required at a median age of 15.5 months (range 5-36 months) in 21% of the children, resulting in a catheter infection rate of 1.74 per 1000 catheter days. None developed an inhibitor on prophylaxis and three patients who had low-titre inhibitors (< 5 Bethesda units) prior to prophylaxis had undetectable inhibitors after prophylaxis. The home-treatment training programme required considerable time and cost. As a result, 87% of the children used peripheral venous access and hospital visits declined as prophylaxis became established. Parents' incentives for prophylaxis were that the children undertook many physical activities and sports previously not recommended, there was less parental anxiety and an overall improvement in the quality of life for the whole family.
引用
收藏
页码:76 / 82
页数:7
相关论文
共 50 条
  • [21] Arteriovenous fistula as stable venous access in children with severe haemophilia
    Mancuso, M. E.
    Berardinelli, L.
    HAEMOPHILIA, 2010, 16 : 25 - 28
  • [22] Forum on: the role of recombinant factor VIII in children with severe haemophilia A
    Franchini, M.
    Coppola, A.
    Molinari, A. C.
    Santoro, C.
    Schinco, P.
    Speciale, V.
    Tagliaferri, A.
    HAEMOPHILIA, 2009, 15 (02) : 578 - 586
  • [23] Prophylaxis for severe haemophilia: clinical and economical issues
    Fischer, K
    Van den Berg, M
    HAEMOPHILIA, 2003, 9 (04) : 376 - 381
  • [24] The benefits of prophylaxis: views of adolescents with severe haemophilia
    Khair, K.
    Gibson, F.
    Meerabeau, L.
    HAEMOPHILIA, 2012, 18 (03) : e286 - e289
  • [25] Factors affecting the Haemophilia Joint Health Score in children with severe haemophilia
    Bladen, M.
    Main, E.
    Hubert, N.
    Koutoumanou, E.
    Liesner, R.
    Khair, K.
    HAEMOPHILIA, 2013, 19 (04) : 626 - 631
  • [26] Adherence to prophylaxis in adult patients with severe haemophilia A
    Bonanad, Santiago
    Garcia-Dasi, Maria
    Aznar, Jose A.
    Eva Mingot-Castellano, Maria
    Jimenez-Yuste, Victor
    Victoria Calle, Ma
    Palma, Antonio
    Fernanda Lopez-Fernandez, Maria
    Marco, Pascual
    Jose Paloma, Maria
    Fernandez-Mosteirin, Nuria
    Galmes, Bernat
    Sanabria, Martin
    Pilar Alvarez, Ma
    HAEMOPHILIA, 2020, 26 (05) : 800 - 808
  • [27] Prophylaxis and treatment of chronic synovitis in haemophilia patients with inhibitors
    Rodriguez-Merchan, E. C.
    Valentino, L.
    Quintana, M.
    HAEMOPHILIA, 2007, 13 : 45 - 48
  • [28] Use of central venous catheters in children with haemophilia: one haemophilia treatment centre experience
    Warrier, I
    BairdCox, K
    Lusher, JM
    HAEMOPHILIA, 1997, 3 (03) : 194 - 198
  • [29] Treatment related factors and inhibitor development in children with severe haemophilia A
    Maclean, P. S.
    Richards, M.
    Williams, M.
    Collins, P.
    Liesner, R.
    Keeling, D. M.
    Yee, T.
    Will, A. M.
    Young, D.
    Chalmers, E. A.
    HAEMOPHILIA, 2011, 17 (02) : 282 - 287
  • [30] When to start and when to stop primary prophylaxis in patients with severe haemophilia
    Astermark, J
    HAEMOPHILIA, 2003, 9 : 32 - 36